New: Final results from the phase 3 HOVON/SAKK trial, comparing R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma
https://t.co/74MH7fEAn6
Delighted to share our work now published on behalf of all co-authors.
Our practice has changed- minimal use of HD-MTX in CNS prophylaxis in aNHL.
Thank you so much to all international collaborators!
https://t.co/3yjHqH3dap
For systemic #CTCL /MF/SS, @BrownHeme we choose #immunotherapy a lot. Reviewing T-cell containment options: kill'em, poison'em, PD1-knock'em. But really we should be turning them against each other... https://t.co/p3DHqmSQBS @OllilaTom#lymsm
East coast friends! @JohnPLeonardMD gave @lymphomatic and I the challenge of debating the utility of CNS prophylaxis in DLBCL. Come learn and watch us duke it out on 04/13 in NYC! Register now: https://t.co/38tvDlUZHb @GreatDebatesCME #bloodcancer#HematologicMalignancies
Check out our study on function, treatment, and outcomes in nursing home patients w/ DLBCL- a population very challenging to manage!
Glad to see this published. This concludes a series of projects on older pts w/ aggressive lymphoma that are very close to my heart! @lymphomatic
@DrLizBrem and I have been working towards figuring out how to solve the conundrum of CNS prophylaxis in #DLBCL through clinical research. It will be great to spar (gently) with arguments pro and con in this @GreatDebatesCME #lymsm
Defining and treating high-grade B-cell #lymphoma, NOS https://t.co/lderjcWpWx
TY to @BrownMedicine@lymphomatic & @BrownUniversity Dr Kurt collab on this review.
2 new classifications out since this was pre-published ~1 year ago but most content still valid/relevant!
#lymsm
@DrAEvens@BrownMedicine@BrownUniversity The HGBL now includes “HGBL with 11q aberration” and HGBL with MYC & BCL6 rearrangements. Welcome to the (still “heterogenous and poorly defined”) family!
#COVID19 booster vaccination leads to seroconversion in over 1/2 of patients w/ hematologic malignancies who had undetectable antibodies to the initial vaccine series. The risk of death appears highest in those with undetectable antibodies. https://t.co/7kZwkxK5Is @OncoAlert
Register at https://t.co/UIDchY830q to hear the latest research & info on aggressive #lymphoma from Dr. David Scott, @lymphomatic, Dr. Neha Mehta-Shah & Dr. Dan Landsburg at #IUCLS2022! Join us live in Chicago April 29-30! @UChicagoCME
We detected clonotypic DNA in the CSF of 36% #DLBCL pts @ high CNS relapse risk. (+)CSF = 29% risk of CNS relapse, (-)CSF assay = 0% risk. If validated - maybe a new way to help personalize CNS prophylaxis? https://t.co/AJ9S3VCXpV #lymsm@BloodAdvances@AdaptiveBiotech@BrownHeme
Defining and Treating High-grade B-cell #lymphoma, NOS | @BloodJournal @ASH_hematology https://t.co/zO87mZ7tkj
Happy to publish this review w/ @RIHospital@BrownUCancer@lymphomatic & Dr Kurt on the challenging topic/entity of HGBL-NOS (1st pic below is correct Fig 1). #lymsm